

Product Datasheet

OTUD6A Antibody - BSA Free

NBP1-91498

Unit Size: 100 ul

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-91498

Updated 2/21/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-91498



NBP1-91498

OTUD6A Antibody - BSA Free

Product Information

Unit Size	100 ul
Concentration	0.5 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.09% Sodium Azide
Isotype	IgG
Purity	Affinity purified
Buffer	PBS, 2% Sucrose
Target Molecular Weight	32 kDa

Product Description


Description	The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Host	Rabbit
Gene ID	139562
Gene Symbol	OTUD6A
Species	Human
Immunogen	Synthetic peptide directed towards the middle region of human OTUD6A. Peptide sequence KMNLENRPPRSSKAHRKRERMESSEERERQESIFQAEMSEHLAGFKREEEE. The peptide sequence for this immunogen was taken from within the described region.

Product Application Details

Applications	Western Blot, Immunocytochemistry/ Immunofluorescence
Recommended Dilutions	Western Blot 1.0 ug/ml, Immunocytochemistry/ Immunofluorescence
Application Notes	Use in ICC/IF reported in scientific literature (PMID:35768646).

Images

Western Blot: OTUD6A Antibody [NBP1-91498] - Titration: 2 ug/ml
Positive Control: Human HeLa Cell line.




Western Blot: OTUD6A Antibody [NBP1-91498] - Titration: 0.2-1 ug/ml,
Positive Control: Jurkat cell lysate.




Western Blot: OTUD6A Antibody [NBP1-91498] - OTUD6A deubiquitinates & affects Drp1 stability. Cells were infected with pLKO-shOTUD6A or mock virus, selected by puromycin for 3 days to eliminate noninfected cells. (A) Depletion of OTUD6A in cells leads to decreased Drp1. Relative OTUD6A (B) & Drp1 (C) expression of (A) was further quantified. (D) Exogenous expression of OTUD6A causes the accumulation of Drp1 in HCT116 (left) & DLD1 (right) cells. (E) Relative Drp1 expression of (D) was further quantified. (F) HCT116 cells transfected with pLKO-shOTUD6A were left untreated or treated with proteasome inhibitor MG132 (10 μ m, 12 h), & the proteins were extracted & subjected to western blotting. (G) Relative Drp1 expression of (F) was further quantified. (H, I) Half-life analysis of Drp1 in HCT116 cells with & without knockdown of OTUD6A. (J, K) Half-life analysis of Drp1 in DLD1 cells expressing OTUD6A. (L) OTUD6A inhibits Drp1 ubiquitination in cells. IB analysis of Ni-NTA pull-down products & WCL derived from HEK293 cells transfected with the indicated constructs. (M) OTUD6A WT but not the mutant C152A deubiquitinates Drp1. The mean \pm SD for three independent experiments is shown. For two groups, data were analyzed by unpaired, two-tailed Student's *t*-test. ***P* < 0.01, ****P* < 0.001. Other data were analyzed by one-way ANOVA, followed by a Bonferroni post hoc test. ***P* < 0.01, ****P* < 0.001. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/33070427>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: OTUD6A Antibody [NBP1-91498] - OTUD6A deubiquitinates & affects Drp1 stability. Cells were infected with pLKO \square shOTUD6A or mock virus, selected by puromycin for 3 days to eliminate noninfected cells. (A) Depletion of OTUD6A in cells leads to decreased Drp1. Relative OTUD6A (B) & Drp1 (C) expression of (A) was further quantified. (D) Exogenous expression of OTUD6A causes the accumulation of Drp1 in HCT116 (left) & DLD1 (right) cells. (E) Relative Drp1 expression of (D) was further quantified. (F) HCT116 cells transfected with pLKO \square shOTUD6A were left untreated or treated with proteasome inhibitor MG132 (10 μ m, 12 h), & the proteins were extracted & subjected to western blotting. (G) Relative Drp1 expression of (F) was further quantified. (H, I) Half \square life analysis of Drp1 in HCT116 cells with & without knockdown of OTUD6A. (J, K) Half \square life analysis of Drp1 in DLD1 cells expressing OTUD6A. (L) OTUD6A inhibits Drp1 ubiquitination in cells. IB analysis of Ni \square NTA pull \square down products & WCL derived from HEK293 cells transfected with the indicated constructs. (M) OTUD6A WT but not the mutant C152A deubiquitinates Drp1. The mean \pm SD for three independent experiments is shown. For two groups, data were analyzed by unpaired, two \square tailed Student's t -test. ** P < 0.01, *** P < 0.001. Other data were analyzed by one \square way ANOVA, followed by a Bonferroni post hoc test. ** P < 0.01, *** P < 0.001. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/33070427>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: OTUD6A Antibody [NBP1-91498] - Decreased cancer cell growth induced by OTUD6A can be partly restored by Drp1 expression. (A) HeLa cells were infected with pLKO \square shOTUD6A, selected by puromycin for 3 days. OTUD6A \square cells were then infected with Drp1 \square WT or Drp1 \square Δ MDVD, selected by hygromycin for 3 days. (B) Fluorescence staining of mitochondrial morphology in HeLa cells stably knockdown OTUD6A & express Drp1 \square WT or Drp1 \square Δ MDVD. The magnification of the images is 400 \times . (C) The length of mitochondrial fragments in the indicated HeLa cells. (D) Cell growth of indicated cells. (E) Colony formation of the indicated cells. (F) Relative colony numbers were further quantified to determine the extent of the colony formation. The mean \pm SD for three independent experiments is shown. Data were analyzed by one \square way or two \square way ANOVA, followed by a Bonferroni post hoc test. * P < 0.05, ** P < 0.01, *** P < 0.001. For image C & F, * P < 0.05, *** P < 0.001 GFP vs WT. # P < 0.05, #### P < 0.001 WT vs. Δ MDVD; ^ P < 0.05, ^^ P < 0.01, ^^ P < 0.001 shGFP + GFP vs. shOTUD6A. For image D, *** P < 0.001 shGFP + GFP vs. shOTUD6A + GFP; ^^ P < 0.001 shGFP + GFP vs. shOTUD6A + Δ MDVD. Scale bar represents 40 μ m. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/33070427>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: OTUD6A Antibody [NBP1-91498] - OTUD6A interacts with Drp1. (A) Drp1 specifically interacts with OTUD6A in cells. IB analysis of IP & WCL derived from HEK293 cells transfected with HA-Drp1 & the indicated Flag-DUBs for 48 h. (B) Overview of OTUD6A & Drp1 structures. (C) OTUD6A WT but not mutant C152A specifically interacts with Drp1. (D) HEK293 cells transfected with the Drp1 constructs were subjected to IP with the anti-HA or anti-Flag antibodies. (E) Drp1 interacts with endogenous OTUD6A in cells. HEK293 cell lysates were subjected to pull down by anti-Drp1 antibody & protein A/G agarose, followed by IB analysis with the indicated antibodies. (F) HeLa cells were fixed & immunostained with anti-Drp1 & anti-OTUD6A before confocal microscopy. The magnification of the images is 400 \times . (G) Quantification of the colocalization between Drp1 & OTUD6A. Scale bar represents 40 μ m. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/33070427>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: OTUD6A Antibody [NBP1-91498] - OTUD6A deubiquitinates & affects Drp1 stability. Cells were infected with pLKO-shOTUD6A or mock virus, selected by puromycin for 3 days to eliminate noninfected cells. (A) Depletion of OTUD6A in cells leads to decreased Drp1. Relative OTUD6A (B) & Drp1 (C) expression of (A) was further quantified. (D) Exogenous expression of OTUD6A causes the accumulation of Drp1 in HCT116 (left) & DLD1 (right) cells. (E) Relative Drp1 expression of (D) was further quantified. (F) HCT116 cells transfected with pLKO-shOTUD6A were left untreated or treated with proteasome inhibitor MG132 (10 μ m, 12 h), & the proteins were extracted & subjected to western blotting. (G) Relative Drp1 expression of (F) was further quantified. (H, I) Half-life analysis of Drp1 in HCT116 cells with & without knockdown of OTUD6A. (J, K) Half-life analysis of Drp1 in DLD1 cells expressing OTUD6A. (L) OTUD6A inhibits Drp1 ubiquitination in cells. IB analysis of Ni-NTA pull-down products & WCL derived from HEK293 cells transfected with the indicated constructs. (M) OTUD6A WT but not the mutant C152A deubiquitinates Drp1. The mean \pm SD for three independent experiments is shown. For two groups, data were analyzed by unpaired, two-tailed Student's t-test. **P < 0.01, ***P < 0.001. Other data were analyzed by one-way ANOVA, followed by a Bonferroni post hoc test. **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/33070427>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: OTUD6A Antibody [NBP1-91498] - OTUD6A deubiquitinates & affects Drp1 stability. Cells were infected with pLKO \square shOTUD6A or mock virus, selected by puromycin for 3 days to eliminate noninfected cells. (A) Depletion of OTUD6A in cells leads to decreased Drp1. Relative OTUD6A (B) & Drp1 (C) expression of (A) was further quantified. (D) Exogenous expression of OTUD6A causes the accumulation of Drp1 in HCT116 (left) & DLD1 (right) cells. (E) Relative Drp1 expression of (D) was further quantified. (F) HCT116 cells transfected with pLKO \square shOTUD6A were left untreated or treated with proteasome inhibitor MG132 (10 μ m, 12 h), & the proteins were extracted & subjected to western blotting. (G) Relative Drp1 expression of (F) was further quantified. (H, I) Half \square life analysis of Drp1 in HCT116 cells with & without knockdown of OTUD6A. (J, K) Half \square life analysis of Drp1 in DLD1 cells expressing OTUD6A. (L) OTUD6A inhibits Drp1 ubiquitination in cells. IB analysis of Ni \square NTA pull \square down products & WCL derived from HEK293 cells transfected with the indicated constructs. (M) OTUD6A WT but not the mutant C152A deubiquitinates Drp1. The mean \pm SD for three independent experiments is shown. For two groups, data were analyzed by unpaired, two \square tailed Student's t \square test. **P < 0.01, ***P < 0.001. Other data were analyzed by one \square way ANOVA, followed by a Bonferroni post hoc test. **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/33070427>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Zhao Y, Huang X, Zhu D et al. Deubiquitinase OTUD6A promotes breast cancer progression by increasing TopBP1 stability and rendering tumor cells resistant to DNA-damaging therapy Cell death and differentiation 2022-06-29 [PMID: 35768646] (WB, ICC/IF, Human)

Shi, L, Liu, J Et al. Deubiquitinase OTUD6A promotes proliferation of cancer cells via regulating Drp1 stability and mitochondrial fission. Mol Oncol 2020-12-01 [PMID: 33070427] (WB, Rat)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-91498

HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control
NBP2-49078PEP	OTUD6A Recombinant Protein Antigen

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-91498

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

